Streetbeat News

Revenues

LXRX

Lexicon Pharmaceuticals has announced a new analysis of its Phase 3 SOLOIST-WHF trial, which shows a positive economic impact on hospitals using alternative payment models. The findings, published in the Journal of Managed Care + Specialty Pharmacy, highlight that INPEFA for heart failure and comorbid diabetes provides significant financial benefits for provider health systems.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 12:07 pm

IMRN

Immuron Limited (NASDAQ: IMRN) announced record sales of its Travelan® product globally, with significant increases in Australia, the USA, and Canada for FY24. The company attributes the growth to increased brand investment and distribution efforts.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 12:06 pm

GNS

Genius Group has completed Phase 1 of a $22 million 'Genius Nation' contract with the Kazakhstan government. This milestone marks significant progress in their partnership and could positively impact the company's financial outlook.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 12:01 pm

MP

Analysts have provided mixed ratings for MP Materials (NYSE:MP) over the past three months, with a recent average 12-month price target of $21.75, down from $25.12. The company faces revenue challenges but shows strong profitability and effective asset utilization.

Portfolio Pulse from Benzinga Insights

July 15, 2024 | 12:01 pm

HP

Analysts have mixed views on Helmerich & Payne (NYSE:HP) with recent ratings showing a mix of 'Somewhat Bullish' and 'Indifferent' sentiments. The average 12-month price target has declined by 7.4% to $41.67. Key analysts from Piper Sandler and Susquehanna have lowered their price targets. Despite a 10.57% decline in revenue over the past three months, the company maintains strong profitability and effective debt management.

Portfolio Pulse from Benzinga Insights

July 15, 2024 | 12:01 pm

WHD

Cactus (NYSE:WHD) has been analyzed by 3 analysts in the last three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased to $54.0. Analysts from Piper Sandler, Citigroup, and Barclays have adjusted their ratings and price targets, reflecting their views on the company's performance. Cactus has shown strong financial performance with notable revenue growth, net margin, ROE, and ROA, and maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

July 15, 2024 | 12:00 pm

EHAB

Enhabit, Inc. (NYSE:EHAB) reported preliminary Q2 adjusted EBITDA of $24.5M-$25.0M and reduced bank debt by $15M. The company also saw an increase in non-Medicare visits shifting to payor innovation contracts. Final results will be reported on Aug. 6, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 11:50 am

GS

Goldman Sachs reported Q2 Global Banking & Markets revenues of $8.18 billion, a 14% increase year-over-year. Investment banking fees rose to $1.73 billion, up 21% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 11:29 am

GS

Goldman Sachs (NYSE:GS) reported Q2 2024 earnings per share (EPS) of $8.62, surpassing the analyst estimate of $8.35. The company also reported sales of $12.730 billion, exceeding the estimate of $12.456 billion. This represents a 16.84% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 11:26 am

MDWD

MediWound Ltd. (NASDAQ:MDWD) announced a $25M strategic private placement financing of 1.45M shares at $17.20/share to advance EscharEx pre-commercial activities. The funds will be used for development and manufacturing capabilities for EscharEx and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 11:09 am